Screener
BioMarin Pharmaceuticals BMRN Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Impairment of assets | — | 2,967 |
| Deferred income taxes | 2,261 | 61,771 |
| Unrealized foreign exchange gains | (4,046) | (5,306) |
| Other | (5,534) | (4,633) |
| Changes in operating assets and liabilities, net of effects of business acquired: | ||
| Accounts receivable, net | (46,005) | (156,124) |
| Inventory | 12,334 | (72,462) |
| Other current assets | (23,589) | (15,092) |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's other income (expense)?
- BioMarin Pharmaceuticals (BMRN) reported other income (expense) of $160K in Q2 2026.
- How has BioMarin Pharmaceuticals's other income (expense) changed year-over-year?
- BioMarin Pharmaceuticals's other income (expense) decreased by 95.2% year-over-year, from $3.37M to $160K.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about BioMarin Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude